SLC2A1 and systemic lupus erythematosus: Hence, pathologies associated with inflammation such as systemic lupus erythematosus, psoriasis, and autoimmune disorders exhibit upregulated levels of expression of GLUT1 suggesting GLUT1 inhibitors offer improvement in the severity of such diseases [34].